Blockade of vascular endothelial growth factor activity suppresses wear debris-induced inflammatory osteolysis

Journal of Rheumatology

Volumn 34, Issue 1, 2007, Pages 27-35

  Ren, Weiping ^a   Zhang, Renwen ^b   Markel, David C ^a   Wu, Bin ^a   Peng, Xin ^a   Hawkins, Monica ^b   Wooley, Paul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stryker Orthopaedics   (United States)

Author keywords

Animal disease models; Hip replacement arthroplasty; Osteolysis; Vascular endothelial growth factor

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 1BETA; RECOMBINANT VASCULOTROPIN; RNA; TUMOR NECROSIS FACTOR ALPHA; ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOPROSTHESIS LOOSENING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HIP ARTHROPLASTY; HISTOLOGY; IMMUNOHISTOLOGY; INFLAMMATION; INFLAMMATORY OSTEOLYSIS; JOINT PROSTHESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOLYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; TOTAL HIP PROSTHESIS;

ANIMALS; BONE RESORPTION; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; INTERLEUKIN-1; MICE; MICE, INBRED BALB C; OSTEOCLASTS; OSTEOLYSIS; POLYETHYLENE; RNA, MESSENGER; SKULL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846206937     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Berry DJ, Harmsen WS, Cabanela ME, Morrey BF. Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: Factors affecting survivorship of acetabular and femoral components. J Bone Joint Surg Am 2002;84:171-7.
2. Keener JD, Callaghan JJ, Goetz DD, et al. Twenty-five-year results after Charnley total hip arthroplasty in patients less than fifty years old: a concise follow-up of a previous report. J Bone Joint Surg Am 2003;85:1066-72.
3. Bauer TW. Particles and peri-implant bone resorption. Clin Orthop 2002;405:138-43.
4. Al Saffar N, Mah JT, Kadoya Y, Revell PA. Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants. Ann Rheum Dis 1995;54:201-8.
5. Goodsell DS. The molecular perspective: VEGF and angiogenesis. Oncologist 2002;7:569-70.
6. Harry LE, Paleolog EM. From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Birth Defects Res Part C Embryo Today 2003;69:363-74.
7. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
8. Tombran-Tink J, Barnstable CJ. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun 2004;316:573-9.
9. Vinores SA, Xiao WH, Zimmerman R, et al. Upregulation of vascular endothelial growth factor (VEGF) in the retinas of transgenic mice overexpressing interleukin-1 beta (IL-1 beta) in the lens and mice undergoing retinal degeneration. Histol Histopathol 2003;18:797-810.
10. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-95.
11. Kunstfeld R, Hirakawa S, Hong YK, et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004;104:1048-57.
12. Nakagawa M, Kaneda T, Arakawa T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000;473:161-4.
13. Henriksen K, Karsdal M, Delaisse JM, Engsig MT. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 2003;278:48745-53.
14. Ren WP, Yang S, Wooley PH. A novel murine model of orthopaedic wear debris-associated osteolysis. Scand J Rheumatology 2004;33:1-10.
15. Wooley PH, Morren R, Andary J, et al. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials 2002;23:517-26.
16. Liao F, Schenkel AR, Muller WA. Transgenic mice expressing different levels of soluble platelet/endothelial cell adhesion molecule-IgG display distinct inflammatory phenotypes. J Immunol 1999;163:5640-8.
17. Ren WP, Wu B, Mayton L, Wooley PH. Polyethylene and methyl methacrylate particle-stimulated inflammatory tissue and macrophages up-regulate bone resorption in a murine neonatal calvaria in vitro organ system. J Orthop Res 2002;20:1031-7.
18. Yang SY, Ren W, Park Y, et al. Diverse cellular and apoptotic responses to variant shapes of UHMWPE particles in a murine model of inflammation. Biomaterials 2002;23:3535-43.
19. Ren WP, Yang SY, Fang HW, et al. Distinct gene expression of receptor activator of nuclear factor-kB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles. Biomaterials 2003;24:4819-26.
20. Wooley PH, Schwarz EM. Aseptic loosening. Gene Ther 2004;11:402-7.
21. Miyanishi K, Trindade MC, Ma T, et al. Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macrophages by orthopaedic biomaterial particles. J Bone Miner Res 2003;18:1573-83.
22. Gallo J, Kaminek P, Ticha V, et al. Particle disease. A comprehensive theory of periprosthetic osteolysis: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2002;146:21-8.
23. Jones LC, Frondoza C, Hungerford DS. Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. J Biomed Mater Res 1999;48:889-98.
24. Jell GM, Al-Saffar N. Does a pro-angiogenic state exist in the bone-implant interface of aseptically loosened joint prosthesis? J Mater Sci Mater Med 2001;12:1069-73.
25. Ikeda M, Hosoda Y, Hirose S, et al. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000;191:426-33.
26. De Bandt M, Ben Mahdi MH, Ollivier V, et al. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol 2003;171:4853-9.
27. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
28. Haywood L, McWilliams DF, Pearson CI, et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003;48:2173-7.
29. Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-8.
30. Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann NY Acad Sci 2002;979:80-93.
31. Ben Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-7.
32. Salven P, Hattori K, Heissig B, Rafii S. Interleukin-1 alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 2002;16:1471-3.
33. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
34. Kato T, Haro H, Komori H, Shinomiya K. Sequential dynamics of inflammatory cytokine, angiogenesis inducing factor and matrix degrading enzymes during spontaneous resorption of the herniated disc. J Orthop Res 2004;22:895-900.
35. Stea S, Visentin M, Granchi D, et al. Cytokines and osteolysis around total hip prostheses. Cytokine 2000;12:1575-9.
36. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res 2001;16:338-47.
37. Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001;97:785-91.
38. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-43.
39. Matsumoto Y, Tanaka K, Hirata G, et al. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol 2002;168:5824-31.
40. Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999;190:293-8.
41. Min JK, Kim YM, Kim YM, et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 2003;278:39548-57.
42. Kodama I, Niida S, Sanada M, et al. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice. J Bone Miner Res 2004;19:200-6.
43. Kaku M, Kohno S, Kawata T, et al. Effects of vascular endothelial growth factor on osteoclast induction during tooth movement in mice. J Dent Res 2001;80:1880-3.